Share this page!

Johnathan Ebben MD, PhD Profile picture
Twitter logo
Sep 2 • 6 tweets • 38 min read
@TumorBoardTues @HosseinBorghaei @ShrutiPatelMD @KevinCalsina @DrRoyHerbstYale @NarjustFlorezMD @MPishvaian @EricaMarieRomn1 @Latinamd @KinhHoang_MD 1/3 #TumorBoardTuesday
Case🎀

Take🏠messages:
In unresectable stage III #NSCLC:
✅ChemoXRT -> IO is SOC
✅STK11 = ⬇️response to IO, but IO still👍🏼after chemoXRT
✅New IO combos- COAST trial ongoing

📚We captured @HosseinBorghaei’s discussion:
twitter.com/i/events/15648…
@TumorBoardTues @HosseinBorghaei @ShrutiPatelMD @KevinCalsina @DrRoyHerbstYale @NarjustFlorezMD @MPishvaian @EricaMarieRomn1 @Latinamd @KinhHoang_MD 2/3 #TumorBoardTuesday
Case🎀

📷 TBT in an image:

We summed it up in a graphic- check out management of unresectable stage III #NSCLC, with updated data from PACIFIC, + exciting data from ongoing COAST trial (evaluating anti-CD73 w ICI; anti-NKG2A w ICI).
@TumorBoardTues @HosseinBorghaei @ShrutiPatelMD @KevinCalsina @DrRoyHerbstYale @NarjustFlorezMD @MPishvaian @EricaMarieRomn1 @Latinamd @KinhHoang_MD @esinghimd @LaurenBzak @jacobadashek @VivekSubbiah @BiagioMd @FSkoulidis 3/3 #TumorBoardTuesday
Case🎀

Next: we’ll delve into choosing a checkpoint inhibitor (which one??) in the 1L setting in PD-L1 high #NSCLC, with experts @NarjustFlorezMD & @ShrutiPatelMD taking us through their clinical approach.

Have a great and safe holiday weekend!
@TumorBoardTues @HosseinBorghaei @ShrutiPatelMD @KevinCalsina @DrRoyHerbstYale @NarjustFlorezMD @MPishvaian @EricaMarieRomn1 @Latinamd @KinhHoang_MD @esinghimd @LaurenBzak @jacobadashek @VivekSubbiah @BiagioMd @FSkoulidis @Florez_Lab @TargetedOnc @sitcancer @DivyaGuptaMD @ADesaiMD @VivekSubbiah @NarjustFlorezMD @ShrutiPatelMD @CharuAggrawalMD @BrunaPellini @KChen_MD
@KinhHoang_MD @JineshGheeya @ParamMD @HannahAlison20 @Drrtee @DrSteveMartin @KevinCalsina
@drgandara @HeekeSimon @n8pennell @findlungcancer @rydhwanah_md @nuria_dios
@TumorBoardTues @HosseinBorghaei @ShrutiPatelMD @KevinCalsina @DrRoyHerbstYale @NarjustFlorezMD @MPishvaian @EricaMarieRomn1 @Latinamd @KinhHoang_MD @esinghimd @LaurenBzak @jacobadashek @VivekSubbiah @BiagioMd @FSkoulidis @Florez_Lab @TargetedOnc @sitcancer @DivyaGuptaMD @ADesaiMD @BrunaPellini @KChen_MD @JineshGheeya @ParamMD @HannahAlison20 @drRTee @DrSteveMartin @drgandara @HeekeSimon @LeciaSequist @Latinamd @DrJNaidoo @FFerrariOk @lucia_zatarain @AboutLungCancer @BairdAM @LaurenByersMD @AndresFCardonaZ @LuisERaez1 @ChristianRolfo @MLJohnsonMD2 @BurrisSkip @RielyMD @JustinGainor @ChiFuJeffYang @ECarcereny @ChrisJ_Shepherd @anguspratt @anu_iris
@TumorBoardTues @HosseinBorghaei @ShrutiPatelMD @KevinCalsina @DrRoyHerbstYale @NarjustFlorezMD @MPishvaian @EricaMarieRomn1 @Latinamd @KinhHoang_MD @esinghimd @LaurenBzak @jacobadashek @VivekSubbiah @BiagioMd @FSkoulidis @Florez_Lab @TargetedOnc @sitcancer @DivyaGuptaMD @ADesaiMD @BrunaPellini @KChen_MD @JineshGheeya @ParamMD @HannahAlison20 @drRTee @DrSteveMartin @drgandara @HeekeSimon @LeciaSequist @DrJNaidoo @FFerrariOk @lucia_zatarain @AboutLungCancer @BairdAM @LaurenByersMD @AndresFCardonaZ @LuisERaez1 @ChristianRolfo @MLJohnsonMD2 @BurrisSkip @RielyMD @JustinGainor @EricaMarieRomn1 @KRASKickers @thenasheffect @ALKpositiveINT @EgidiusLambrech @EugeneManley

• • •

Missing some Tweet in this thread? You can try to force a refresh
　

Keep Current with Johnathan Ebben MD, PhD

Johnathan Ebben MD, PhD Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @JohnEbbenMDPhD

Johnathan Ebben MD, PhD Profile picture
Aug 19
@TumorBoardTues @hoperugo @laura_huppert @ErikaHamilton9 @MPishvaian @PTarantinoMD @stolaney1 @drteplinsky @JaniceTNBCmets @UCSFCancer 2/3 #TumorBoardTuesday
Thurs Case🎀

Take🏠:
✅HER2 LOW= IHC1+ OR IHC2+ w - ISH (67% HR+!)
✅T-DXd= after 1L chemo in HER2 low
✅Careful monitoring for ILD!

📚We captured @hoperugo & @LauraHuppert’s discussion in below:

twitter.com/i/events/15588…

twitter.com/i/events/15601…
@TumorBoardTues @hoperugo @laura_huppert @ErikaHamilton9 @MPishvaian @PTarantinoMD @stolaney1 @drteplinsky @JaniceTNBCmets @UCSFCancer @LauraHuppert 2.75/3 #TumorBoardTuesday

Check out this graphic outlining the key role for ADCs in the tx of HER2 low #MBC after prior 1L chemo and endocrine therapy.

Hoping for even more changes in the near future w
DB-06! Image
@TumorBoardTues @hoperugo @laura_huppert @ErikaHamilton9 @MPishvaian @PTarantinoMD @stolaney1 @drteplinsky @JaniceTNBCmets @UCSFCancer @LauraHuppert @esinghimd @HemoncUcsf @UICHemOnc @Hopkins_HemOnc @TheFellowOnCall @jacobadashek 3/3 #TumorBoardTuesday
Special thanks to @hoperugo & @laura_huppert. It is a privilege to hear from experts who are re-defining tx for #breastcancer w next gen ADCs!

Join us on August 30 as @HosseinBorghaei discusses the latest in stage III #NSCLC!
Read 7 tweets
Johnathan Ebben MD, PhD Profile picture
Aug 12
@TumorBoardTues @brian_rini @DrChoueiri @RenoHemonc @tompowles1 @CParkMD @RCCadvocate @EricaMarieRomn1 @jacobadashek 2/5 #TumorBoardTuesday
Thursday Case🎀

Take🏠:

✅High risk feat= consider adj tx
✅Sunitinib= FDA ☑️; can be hard to tolerate
✅Pembro= FDA ☑️ w DFS benefit
✅irAE mgmt - gr3+= steroids

📚We captured @brian_rini’s discussion in this moment: twitter.com/i/events/15552…
@TumorBoardTues @brian_rini @DrChoueiri @RenoHemonc @tompowles1 @CParkMD @RCCadvocate @EricaMarieRomn1 @jacobadashek 3/5 #TumorBoardTuesday
Thursday Case🎀

📷 TBT in an image: 👀out a clinical algorithm 📊for adj therapy in #RCC.

Some pearls re: irAE mgmt & addtl info to help choose a patient appropriate adjuvant regimen! Image
@TumorBoardTues @brian_rini @DrChoueiri @RenoHemonc @tompowles1 @CParkMD @RCCadvocate @EricaMarieRomn1 @jacobadashek @esinghimd @PaulCrispenMD @apolo_andrea @AmandaNizamMD 4/5 Thurs Case 🎀
#PostTest Q2️⃣ #CME #TumorBoardTuesday
FREE CME🔗 integrityce.com/tbt
CME eval🔗 integrityce.com/TBTeval

Now that you’ve reviewed- try your hand at #CME:

🤨Which strategy would you use for a pt receiving pembrolizumab experiencing #IBD colitis (grade 3)?
Read 10 tweets
Johnathan Ebben MD, PhD Profile picture
Aug 5
@TumorBoardTues @dradityabardia @ArielleMedford @Latinamd @EricaMarieRomn1 @HillStirSci @ErikaHamilton9 @stolaney1 @PTarantinoMD 2/5 #TumorBoardTuesday
Thurs Case🎀

Take🏠messages

✅BRCAm= 10-20% of TNBC!
✅PD-L1 CPS>10= PFS & OS benefit w/ IO in mTNBC
✅PARPi= PFS benefit
✅Biomarkers, side effects, pt pref key

📚We captured much of @dradityabardia @ariellemedford’s discussion: twitter.com/i/events/15548…
@TumorBoardTues @dradityabardia @ArielleMedford @Latinamd @EricaMarieRomn1 @HillStirSci @ErikaHamilton9 @stolaney1 @PTarantinoMD 3/5 #TumorBoardTuesday
Thursday Case🎀

How do you choose IO vs PARPi in #TNBC w #BRCA mutation? Check out the summary and algorithm below!
Important to know there are more 2L options as well, including sacituzumab-gov & other ADCs. New trials evaluating IO+ PARPi–stay tuned!
@TumorBoardTues @dradityabardia @ArielleMedford @Latinamd @EricaMarieRomn1 @HillStirSci @ErikaHamilton9 @stolaney1 @PTarantinoMD @DFCI_BreastOnc @oreganruth @marina_sharifi @JaniceTNBCmets @OncBrothers @Myshastry @BRCAUmbrella 4/5 #TumorBoardTuesday

Remember #TumorBoardTuesday offers AMA & now MOC credit for FREE! Don’t forget to answer the polls👇🏽
Then click this link to quickly request your credit!
CME eval🔗: integrityce.com/tbteval
ALL CME 🔗: integrityce.com/tbt

Read 11 tweets
Johnathan Ebben MD, PhD Profile picture
Jul 22
@TumorBoardTues @PTarantinoMD @CaterinaSpo @ADesaiMD @silke4senate @DrLauraEsserman @BRCAUmbrella @hoperugo @SusanGKomen @ErikaHamilton9 @stolaney1 1/8 #TumorBoardTuesday

🔬🧬Discussion on 1L treatment for BRCA+ #MBC led by @PTarantinoMD @CaterinaSpo #BreastCancer

➡️Here’s the week's Thursday Case 🎀

👉Don’t forget your🆓 #CME credit by answering 1 quick❓
CME🔗: integrityce.com/tbt
CME eval🔗: integrityce.com/tbteval
@TumorBoardTues @PTarantinoMD @CaterinaSpo @ADesaiMD @silke4senate @DrLauraEsserman @BRCAUmbrella @hoperugo @SusanGKomen @ErikaHamilton9 @stolaney1 2/8 #TumorBoardTuesday
Thursday Case🎀

Take🏠messages for germline #BRCAm & 2L tx in #BreastCancer
✅BRCAm fairly common - 10-20% of #TNBC
✅PARPi approved in met, BRCAm dz
✅Fast responses, with ORR > chemo

📚Much of @PTarantinoMD @CaterinaSpo’s chat👇🏽
twitter.com/i/events/15487…
@TumorBoardTues @PTarantinoMD @CaterinaSpo @ADesaiMD @silke4senate @DrLauraEsserman @BRCAUmbrella @hoperugo @SusanGKomen @ErikaHamilton9 @stolaney1 2.33/8 #TumorBoardTuesday
Thursday Case🎀

Take🏠messages (continued):

✅Toxicities for 🤢, myelosuppression- managed w ⬇️ reduction, tx holiday
‼️(remember 3-5% risk of MDS/AML)‼️
Read 15 tweets
Johnathan Ebben MD, PhD Profile picture
Jul 15
@TumorBoardTues @CharuAggarwalMD @ADesaiMD @Latinamd @PTarantinoMD @LealTiciana @NarjustFlorezMD 1/8 #TumorBoardTuesday
🔬🧬@CharuAggrawalMD @ADesaiMD taught us about EGFR mutations in #LungCancer–specifically, new 2L strategies for EGFRexon20m.

➡️Here's this week's Thursday Case🎀
Pick up your 🆓#CME
ALL CME 🔗: integrityce.com/tbt
CME eval🔗: integrityce.com/tbteval
@TumorBoardTues @CharuAggarwalMD @ADesaiMD @Latinamd @PTarantinoMD @LealTiciana @NarjustFlorezMD 2/8 #TumorBoardTuesday
Thurs Case🎀

Take🏠messages:
We discussed #EGFR mutations in #LungCancer
✅Not all EGFR mutations are the same!
✅Osimertinib=tx for most activating EGFR mutations
✅…but exon20insmut more resistant to TKIs
✅Amivantamab, mobocertinib= 2L strategies
@TumorBoardTues @CharuAggarwalMD @ADesaiMD @Latinamd @PTarantinoMD @LealTiciana @NarjustFlorezMD 2.5 / 8 #TumorBoardTuesday

📚We captured as much of @CharuAggrawalMD @ADesaiMD’s discussion as we could in this moment: twitter.com/i/events/15463…

CRITICAL point: if you don’t look, you won’t know! RNA based NGS recommended for 🫁cancer cases to identify actionable mut
Read 17 tweets
Johnathan Ebben MD, PhD Profile picture
Jul 1
@TumorBoardTues @Dr_RShatsky @PTarantinoMD @ErikaHamilton9 @UCSDCancer @KariWisinski_MD @marina_sharifi @JPoteralaMD @LaurenBzak @benjiwal @drteplinsky @MarkRobsonMD 2/11 #TumorBoardTuesday
Thurs Case🎀
Take🏠:
#TNBC &neoadjuvant tx
✅KEYNOTE-522= new standard of care
– Pembro+chemo in neoadj= BEST pCR so far
– Caveat: only for T2+ TNBC
✅Adding pembro may have ⬆️benefit in RCB II
📚We captured much of chat:
p1: twitter.com/i/events/15423…
@TumorBoardTues @Dr_RShatsky @PTarantinoMD @ErikaHamilton9 @UCSDCancer @KariWisinski_MD @marina_sharifi @JPoteralaMD @LaurenBzak @benjiwal @drteplinsky @MarkRobsonMD 3/11 #TumorBoardTuesday
Thurs Case🎀
Take🏠msgs (cont’d):
✅IO NOT shown to add benefit in metastatic dz
– Atezolizumab approval in mTNBC withdrawn
✅Standard of care – multi-d team
✅No current evidence to hold IO pre-op
P2: twitter.com/i/events/15425…
@TumorBoardTues @Dr_RShatsky @PTarantinoMD @ErikaHamilton9 @UCSDCancer @KariWisinski_MD @marina_sharifi @JPoteralaMD @LaurenBzak @benjiwal @drteplinsky @MarkRobsonMD 4/11 #TumorBoardTuesday
Thurs Case🎀
Take🏠messages (cont’d):
✅THINK about side FX, including fertility
— Ovarian suppression may preserve fertility while undergoing neoadj tx
✅Patient voice is MOST important- pts define “acceptable tox,” not 🩺
Read 16 tweets

Did Thread Reader help you today?

Support us! We are indie developers!

This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us on Twitter!

:(